comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 02:27:24 - browse：1871

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Biden White House, tech companies launch new safeguards around emerging AI technology

leisure time

WSS

Florida babysitter arrested over hot car death, authorities say

Top private equity targets in 2023: cardiology, clinical trials, lasers

Hey, doctors: Don't be no

The CDC's new social media misinformation war

New chief aims to remake Sanofi Genzyme

New chart reveals military’s vast involvement in Operation Warp Speed

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Amgen, Regeneron, BGI Group and more

23andMe had bad news about my health. I wish a person had delivered it

AI gets buy

How one medical school became remarkably diverse

Biden White House, tech companies launch new safeguards around emerging AI technology

Activists slam private health insurers over coverage restrictions

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

focus

The CDC's new social media misinformation war

Medicare Advantage plans can’t deny care with AI, CMS warns

Texas Medical Board asked to define abortion emergency exception

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

A new deal aims to ramp up use of AI in rehab care decisions

leisure time

hotspot

leisure time

explore